Australian company Immutep (ASX:IMM) has reported positive results from a clinical trial of its LAG-3 immunotherapy in combination with MSD's PBS-listed anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Positive results for Australian company's cancer candidate in combination with MSD's Keytruda
May 18, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech